Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer

“Our goal was very clear from the beginning, which was to develop a user-friendly simple chat-like interface that would provide specific high-quality answers to questions that our members would bring, utilizing only our content,” said Clifford A. Hudis, CEO of the American Society of Clinical Oncology and executive vice chair of the Conquer Cancer Foundation.

October 22, 2025

Vol.51 No.38

Drugs & Targets

ARPA-H selects Tempus as contract research organization for ADAPT Program

Tempus AI was selected by the Advanced Research Projects Agency for Health to provide testing and contract research organization services in support of the agency’s Advanced Analysis for Precision Cancer Therapy program.

October 17, 2025

Vol.51 No.38

Drugs & Targets

Algen Biotechnologies, AstraZeneca form AI drug discovery partnership

Algen Biotechnologies and AstraZeneca are entering into a multi-target research collaboration to advance AI-powered drug discovery in immunology.

October 17, 2025

Vol.51 No.38

Guest Editorial

ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology

Cancer care is evolving at an unprecedented pace. Practitioners feel the mounting pressures daily: rising cancer rates—particularly in younger patients—a growing population of older cancer survivors, rapid growth in new care and treatment options, and navigating heightened fiscal constraints and uncertainty.

October 10, 2025

Vol.51 No.37

By Clifford A. Hudis and Thomas Kurian

Cancer Policy

ASCO report shows decrease in the number of oncologists relative to aging population

A report by the American Society of Clinical Oncology points to a growing challenge in cancer care access driven by a widening gap between the number of available oncologists and increasing patient demand.

October 10, 2025

Vol.51 No.37

By Claire Marie Porter

Clinical Roundup

OSUCCC–James researchers are using AI to better predict, diagnose lobular cancer

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at the Ohio State University Comprehensive Cancer Center is using artificial intelligence to devise new ways of predicting which patients will develop an aggressive and difficult-to-detect form of breast cancer called lobular cancer, which represents one in every 10 breast cancers diagnosed in the United States.

October 10, 2025

Vol.51 No.37

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

YOU MAY BE INTERESTED IN

Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer

ARPA-H selects Tempus as contract research organization for ADAPT Program

Algen Biotechnologies, AstraZeneca form AI drug discovery partnership

ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology

ASCO report shows decrease in the number of oncologists relative to aging population

OSUCCC–James researchers are using AI to better predict, diagnose lobular cancer

Renew today!

Subscriber content

Never miss an issue!

Login